Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06007937 · ClinicalTrials.gov registry record · Phase 1

A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

A Phase 1 study of Non-Small Cell Lung Cancer and Metastatic, sponsored by Memorial Sloan Kettering Cancer Center.

Recruiting
Registry status
Phase 1
Development phase
56
Enrollment target
6
Study locations

NCT06007937 is a Phase 1 study of Non-Small Cell Lung Cancer and Metastatic that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 56 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (92% lower). The trial reports 6 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06007937, a Phase 1 study of Non-Small Cell Lung Cancer and Metastatic, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.

RECRUITING
Registry status
Phase 1
Development phase
56 participants
Enrollment target
6
Study locations

Study Summary

This study will test the safety of the combination of ramucirumab and lorlatinib. The researchers will test one or two different doses of lorlatinib in combination with ramucirumab to find the drug combination dose that causes few or mild side effects in participants. Once the researchers find this dose, they can test it in future participants to see if it is effective in treating their metastatic ALK-rearranged NSCLC. The researchers are also looking to see whether there are specific genes or DNA sequences associated with a response to treatment with lorlatinib and ramucirumab.

Conditions Studied

Non-Small Cell Lung Cancer Metastatic Recurrent

Interventions

  • DRUG Ramucirumab
  • DRUG Lorlatinib

Study Locations (6)

New York

  • Memorial Sloan Kettering Cancer Center Suffolk - Commack (All Protocol Activities) - Commack
  • Memorial Sloan Kettering West Harrison (All Protocol Activities) - Harrison
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
  • Memorial Sloan Kettering Nassau (All Protocol Activities) - Rockville Centre

New Jersey

  • Memorial Sloan Kettering Monmouth (All Protocol Activities) - Middletown
  • Memorial Sloan Kettering Bergen (All Protocol Activities) - Montvale

Trial Details

FieldValue
Enrollment Target 56 participants
Start Date 2023-08-17
Est. Completion 2028-08-17
Phase Phase 1

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06007937

The ClinicalTrials.gov registry entry for NCT06007937 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (92% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Ramucirumab is the first listed.

NCT06007937 reports 6 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.

Frequently Asked Questions

What is clinical trial NCT06007937 about?

NCT06007937 is a clinical study titled "A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer". This study will test the safety of the combination of ramucirumab and lorlatinib. The researchers will test one or two different doses of lorlatinib in combination with ramucirumab to find the drug combination dose that causes few or mild side effects in participants. Once the researchers find this ...

What is the current status of trial NCT06007937?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2023-08-17. Estimated completion is 2028-08-17.

What conditions does trial NCT06007937 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Metastatic, Recurrent.

What interventions are being tested in trial NCT06007937?

The interventions under investigation include: Ramucirumab (DRUG), Lorlatinib (DRUG).

Who is sponsoring clinical trial NCT06007937?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06007937 being conducted?

This trial has 6 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Small Cell Lung Cancer

All registered trials for this condition

Metastatic

All registered trials for this condition

New Jersey

All trials with a study site in New Jersey

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.